Small molecule · Degrader of SMARCA2 · developed by Prelude Therapeutics
PRT3789 is a targeted protein degrader that links a SMARCA2-binding moiety to an E3 ubiquitin ligase-binding moiety, inducing proteasome-mediated degradation of SMARCA2 (BRM). It is being studied in SMARCA4-deleted cancers, which depend on SMARCA2 for survival, including solid tumors, esophageal cancer and non-small cell lung cancer.
Summary written with AI from the sources listed at the end of this page.
| Trial | Phase | Condition | Status | Sponsor |
|---|---|---|---|---|
| NCT06682806 | Phase 2 | Advanced Solid Tumor | Terminated | PRLD |
Trials of the companies BioRadar tracks, from ClinicalTrials.gov, most advanced phase first.
Advanced Solid TumorEsophageal CancerMetastatic Solid TumorNon-small Cell Lung CancersSMARCA4 Gene Mutation
Updated Oct 25, 2026. Something wrong or missing? Report it on the PRLD page.
See PRLD's upcoming FDA decisions, trial readouts, cash runway and dilution risk, updated every day from SEC, FDA and ClinicalTrials.gov filings.
PRLD catalysts and pipeline →